Trial Details
Ide-cel + Pomalidomide +
Anti–CD-38 + Dexamethasone
Recruiting
Area of Research: R/R MM
Phase 1/2

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

Brief Summary:

This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to determine the safety, tolerability, efficacy, PK of bb2121 in combination with other therapies in adult subjects with R/RMM.The following combinations will beArm A will test bb2121 in combination with CC-220 (± low-dose dexamethasone) Arm B will test bb2121 in combination with BMS-986405 (JSMD194) Arm C will test bb2121 in combination with one of the following standard triplet regimens: 1) Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (DPd); 2) Pomalidomide (POM) in combination with bortezomib (BTZ) and low-dose dexamethasone (PVd)Combination agents being tested may be administered before, concurrently with and/or following (ie, maintenance) bb2121 infusion.The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose expansion may occur in one or more arms.

For more information, please contact the recruiting sites directly.
If there is no contact information, please email: Clinical.Trials@bms.com. The first line of the email MUST contain the NCT # and Site #.

25 locations available.
close-icon

Log In

Log in below to access your account on BMS Science or Bolder Science. If you have an existing Bolder Science account, please use your login credentials for that account here.

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create Account

Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.

  • 8 characters minimum
  • First character cannot be a number
  • Last character cannot be a number